Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04955990 · ClinicalTrials.gov registry record · Phase 4
A Study of Real-world Cohort of Pulmonary Arterial Hypertension (PAH) Participants
A Phase 4 study, sponsored by Actelion.
- Terminated
- Registry status
- Phase 4
- Development phase
- 232
- Enrollment target
NCT04955990: Clinical Trial Phase 4 study, sponsored by Actelion.
NCT04955990 is a Phase 4 study that was terminated before completion, run by Actelion. The registered enrollment target is 232 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04955990, a Phase 4 study, was terminated before completion, sponsored by Actelion.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 232 participants
- Enrollment target
Study Summary
This study is designed to describe pulmonary arterial hypertension (PAH) participants in terms of their clinical characteristics, therapies used, disease progression, and outcomes (example, death, hospitalization, risk category for predicted mortality risk, and patient-reported outcomes \[PROs\]) in real-world clinical practice. This study will collect high-quality real-world data that may be used as a stand-alone dataset or in combination with other studies to address relevant research questions (example, serve as an external control dataset to another study) to support development and access to PAH therapies, as well as to contribute to the knowledge base of PAH through publications.
Primary Outcome
Time to all cause death will be reported. All-cause death defined as deaths due to any cause.
Interventions
- OTHER PAH Therapies
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 232 participants |
| Start Date | 2021-10-14 |
| Est. Completion | 2022-12-20 |
| Phase | Phase 4 |
Why NCT04955990 stopped before completion
NCT04955990 is an interventional study that assigns participants to a tested intervention. The registered 232 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (55% lower).
The record links to 0 conditions, and to 1 intervention - of which PAH Therapies is the first listed.
NCT04955990 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04955990 about?
NCT04955990 is a clinical study titled "A Study of Real-world Cohort of Pulmonary Arterial Hypertension (PAH) Participants". This study is designed to describe pulmonary arterial hypertension (PAH) participants in terms of their clinical characteristics, therapies used, disease progression, and outcomes (example, death, hospitalization, risk category for predicted mortality risk, and patient-reported outcomes \[PROs\]) in...
What is the current status of trial NCT04955990?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 232 participants. The study started on 2021-10-14. Estimated completion is 2022-12-20.
What interventions are being tested in trial NCT04955990?
The interventions under investigation include: PAH Therapies (OTHER).
Who is sponsoring clinical trial NCT04955990?
This trial is sponsored by Actelion, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04955990's enrollment target sits among peer trials
232 370th of 2000 higher than 1,631 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01356290 · 232 participants · Phase 2
Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
- NCT04753359 · 232 participants · NA
Mediterranean Diet and Weight Loss: Targeting the Bile Acid/Gut Microbiome Axis to Reduce Colorectal Cancer
- NCT04770870 · 232 participants · NA
Post Approval Study2: Hintermann Series H3 Total Ankle Replacement System
- NCT05948943 · 232 participants · Phase 2
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI